Ban on Puberty Blockers for Minors in the United Kingdom
The United Kingdom has banned new prescriptions of puberty blockers for minors with gender dysphoria indefinitely, citing weak medical evidence and significant risks associated with the medication. Transgender activists have condemned the ban.
Key Points
- Indefinite ban on new prescriptions of puberty blockers in the UK
- Based on weak medical evidence and significant risks associated with the medication
- Transgender minors already on the medication can continue, while cisgender minors with early puberty can still receive prescriptions
- Ban to be revisited in 2027 after clinical trials
Pros
- Ensures children's healthcare is evidence-led
- Addresses concerns about unproven benefits and significant risks of puberty blockers
Cons
- Transgender activists condemn the ban as medical negligence
- May limit treatment options for minors with gender dysphoria